<DOC>
	<DOCNO>NCT01313936</DOCNO>
	<brief_summary>This pilot study determine whether dos 15 mCi/kg 18 mCi/kg 131I-MIBG tolerable give irinotecan/vincristine one week schedule child young adult high-risk refractory/relapsed neuroblastoma .</brief_summary>
	<brief_title>High-Dose 131I-MIBG Therapy Combined With Vincristine Five Days Irinotecan Resistant/Relapsed Neuroblastoma</brief_title>
	<detailed_description>131I-metaiodobenzylguanidine ( 131I-MIBG ) active therapy patient widely metastatic , treatment-resistant neuroblastoma , response rate 20-40 % dos ( &gt; 15mCi/kg ) require stem cell rescue . Irinotecan topoisomerase I inhibitor single-agent chemotherapeutic activity neuroblastoma pediatric solid tumor phase I II clinical trial . With protracted schedule ( e.g . daily 5 days/week x 2 week ) , major dose-limiting toxicity diarrhea . With short schedule , myelosuppression become dose-limiting . In adult solid tumor , irinotecan effective radiosensitizer currently evaluate Children 's Oncology Group purpose rhabdomyosarcoma protocol incorporate external beam radiotherapy . Compared single-agent 131I-MIBG , combination topotecan ( related camptothecin ) 131I-MIBG demonstrated superior pre-clinical activity mouse xenograft model neuroblastoma . This combination unexpected toxicity pilot clinical study . We complete clinical trial vincristine , irinotecan , 131I-MIBG utilized irinotecan protract schedule ( 5 day per week x 2 week ) . The rationale schedule provide great degree overlap radiation sensitizer ( irinotecan ) radiation exposure provide follow 131I-MIBG infusion . This combination show tolerable dos 18 mCi/kg 131I-MIBG . However , patient experience grade 2 3 diarrhea would customary dose schedule irinotecan use trial . It therefore interest determine whether combination irinotecan , vincristine , 131I-MIBG well tolerate use irinotecan high dos shorter schedule . The current standard schedule Children 's Oncology Group protocols combination vincristine , irinotecan high dose five , rather 10 day . In current pilot study , evaluate tolerability anti-tumor activity combination use irinotecan give daily 5 day . Two 131I-MIBG dose level evaluate . This study provide basis future randomize trial .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>Age : Patients must &gt; 1 year &lt; 30 year age register study . Diagnosis : Patients must diagnosis neuroblastoma either histologic verification neuroblastoma and/or demonstration tumor cell bone marrow increase urinary catecholamine . Disease status : Patients must highrisk neuroblastoma least ONE following : 1 . Recurrent/progressive disease time . Biopsy require , even partial response intervene therapy except patient one site MIBGavid disease radiate within precede two month . Such patient require biopsy confirmation residual active disease , positive bone marrow biopsy adequate confirmation residual active disease . 2 . Refractory disease ( i.e . less partial response frontline therapy , include minimum 4 cycle induction chemotherapy ) . No biopsy require eligibility study . 3 . Persistent disease least partial response frontline therapy ( i.e . patient least partial response frontline therapy still residual disease MIBG scan , CT/MRI , bone marrow ) . Patients category REQUIRED biopsy ( bone marrow biopsy include ) least one residual site demonstrate viable neuroblastoma . 131IMIBG Uptake : Patients must evidence MIBG uptake tumor ≥ one site within 4 week prior entry study subsequent intervening therapy . Hematopoietic stem cell : Patients must adequate unpurged peripheral blood hematopoietic stem cell product , minimum 2 X 106 CD34+ cells/kg available . Having backup 2.0 x 106 viable CD34+ cells/kg unpurged PBSC recommend require . The use purge stem cell autologous bone marrow donor source allow . The use PBSC identical twin allow . Performance life expectancy : Must life expectancy least 6 week Lansky Karnofsky score least 60 . Prior therapy : Patients must fully recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study . 1 . Myelosuppressive chemotherapy and/or biologics : Patients require complete reinduction chemotherapy prior study entry follow relapse . Last dose myelosuppressive biologic therapy give least 2 week start date irinotecan protocol . 2 . Radiation : Patients must receive radiation minimum two week prior study entry . Patients receive radiation site MIBGavid disease within two month study entry require biopsy confirmation residual active disease , positive bone marrow biopsy adequate confirmation residual active disease . A minimum 3 month require follow prior large field radiation therapy ( i.e . craniospinal therapy , total lung , &gt; 50 % marrow space ) . Patients exclude received whole abdominal radiation TBI ( total body irradiation ) . 3 . Stem Cell Transplant ( SCT ) : Patients eligible three month autologous stem cell transplant . Patients status postallogeneic stem cell transplant exclude . Must meet adequate bone marrow function definition ( see organ function requirement , ) postmyeloablative therapy . 4 . Prior 131IMIBG therapy : Patients may receive prior MIBG therapy , though cumulative lifetime dose exceed 18 mCi/kg prior study entry . Patients must receive MIBG combination irinotecan . For patient previously treat MIBG , least 6 month must elapse since last MIBG therapy . 5 . Growth factor ( ) : All cytokine hematopoietic growth factor must discontinue minimum 7 day prior start date irinotecan protocol . 6 . Prior irinotecan vincristine therapy : allow , subject recovery adequate bone marrow function specify protocol . Concomitant Therapy Restrictions : Patients must receive anticancer agent radiotherapy time study entry study . Enzymeinducing anticonvulsant ( phenobarbital , phenytoin , carbamazepine ) must use may interfere irinotecan metabolism . Nonenzyme induce anticonvulsant ( Keppra , etc . ) use discussion study chair . The use high dose dexamethasone use aprepitant antiemetic recommend due effect irinotecan metabolism . Hematologic function : a. ANC : &gt; 750/uL ( hematopoietic growth factor within 7 day start date irinotecan protocol ) b. Platelet count : &gt; 50,000/µl , transfusion independent ( defined platelet transfusion one week ) . c. These criterion must meet patient , regardless bone marrow involvement tumor . Renal function : a. Glomerular Filtration Rate ( GFR ) 1224hr Creatinine Clearance &gt; = 60 ml/min/1.73 m² , OR b. Ageadjusted serum creatinine &lt; 1.5 x normal age ( see ) : Age Maximum Serum Creatinine ( mg/dL ) &lt; 5 year 0.8 &gt; 5 &lt; 10 year 1.0 &gt; 10 &lt; 15 year 1.2 &gt; 15 year 1.5 Liver function : . Total bilirubin &lt; = 1.5 x normal age , b. SGPT ( ALT ) SGOT ( AST ) &lt; 3 x upper limit normal Cardiac function : Normal ejection fraction ( &gt; =55 % ) document either echocardiogram radionuclide MUGA evaluation OR normal fractional shortening ( &gt; = 27 % ) document echocardiogram . Lung function : Normal lung function dyspnea rest , exercise intolerance , pleural effusion oxygen requirement . Reproductive function : All postmenarchal female must negative urine serum betaHCG . Males female reproductive age childbearing potential must use effective contraception duration participation . Coexisting medical condition : Patients ongoing serious medical issue must approve study chair prior registration . Pregnant lactating . Patients status postALLOGENEIC stem cell transplant NOT eligible . Patients , opinion investigator , may able comply safety monitoring requirement study . Patients disease major organ system would compromise ability withstand therapy . Patients hemodialysis . Patients document allergy 3rd generation cephalosporin . Patients must active diarrhea ( define &gt; Grade 2 per CTCAE v4 [ Grade 2 = increase 46 stools/day baseline ] ) . Patients active uncontrolled infection , include C. difficile , &gt; grade 3 per CTCAE v4 . Patients prolonged antifungal therapy eligible culture biopsy negative suspect radiographic lesion meet organ function criterion . Patients and/or family physically psychologically unable cooperate radiation safety isolation . Patients receive prior total body whole abdominal radiation . Patients receive prior 131IMIBG therapy combination irinotecan .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Neuroblastoma</keyword>
	<keyword>MIBG</keyword>
	<keyword>131I-MIBG</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Resistant</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Treatment</keyword>
	<keyword>UCSF</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Oncology</keyword>
</DOC>